K-numberK250803
Device nameDeepblue Multi-Drug Urine Test Cup; Deepblue Home Muti-Drug Urine Test Cup
ApplicantAnhui Deepblue Medical Technological Co., Ltd.
Product codeNGL
Device classClass II
Decision dateApr 15, 2025
DecisionSubstantially Equivalent
Regulation862.3650
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Deepblue Multi-Drug Urine Test Cup is a rapid lateral flow immunoassay that qualitatively detects 17 drugs and metabolites (including amphetamine, cocaine, opiates, benzodiazepines, THC, and others) in human urine at specified cutoff concentrations. The Deepblue Home Multi-Drug Urine Test Cup is a similar rapid qualitative immunoassay for preliminary detection of drugs in urine. Both are available in single or multi-test cup configurations, optionally with on-board adulteration/specimen validity tests, and are intended for prescription use or over-the-counter use.

Technological characteristics

Both devices use competitive binding, lateral flow immunochromatographic assays based on antigen-antibody reactions and are qualitative tests using human urine specimens. The key difference from the predicate (Healgen Accurate Urine Drug Screen Dip Card, K240686) is physical form: the Deepblue devices are cup-format in ready-to-use sealed aluminum pouches, whereas the predicate is a dip card format. The Deepblue devices include Fentanyl detection (at 1 ng/mL cutoff), which the predicate does not.

Test standards cited

Not stated in this summary.

Substantial equivalence argument

Substantial equivalence is established through identical test methodology (competitive lateral flow immunochromatography), identical specimen type (human urine), identical qualitative purpose, and overlapping target drugs at equivalent cutoff concentrations (except fentanyl, which is a new analyte of concern). The submitter demonstrated equivalence through comprehensive analytical validation including precision testing across three lots and multiple concentrations, analytical specificity via cross-reactivity and interference studies, method comparison against LC-MS/MS on clinical samples, and lay-user studies showing >90% agreement at all concentration levels. The physical format change (cup versus dip card) does not alter the assay principle or performance; both are immunochromatographic lateral flow devices designed for the same preliminary drug-screening application.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →